[[(2s,5r)-5-(4-Azanyl-5-Fluoranyl-2-Oxidanylidene-Pyrimidin-1-Yl)oxolan-2-Yl]methoxy-Oxidanyl-Phosphoryl] Phosphono Hydrogen Phosphate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷酸
• 英文名称: [[(2s,5r)-5-(4-Azanyl-5-Fluoranyl-2-Oxidanylidene-Pyrimidin-1-Yl)oxolan-2-Yl]methoxy-Oxidanyl-Phosphoryl] Phosphono Hydrogen Phosphate
• 英文别名: [[(2S,5R)-5-(4-amino-5-fluoro-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
• 化学式: C₉H₁₅FN₃O₁₂P₃
• 分子量: 469.15
• InChiKey: ARRTZUVEPRJLPK-CAHLUQPWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.4
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  228
• 氢给体数：
  5
• 氢受体数：
  13

文献信息

• Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions
  申请人：COMMUNAUTE ECONOMIQUE EUROPEENNE (CEE)

  公开号：EP0517986A1

  公开（公告）日：1992-12-16

  The invention relates to compositions comprising transformed erythrocytes containing phosphorylated compounds, which do not naturally occur in a human or animal organism, said compounds having the properties of: inhibiting the reverse transcriptase, and being stable in erythrocytes. The compositions of the invention are useful for the treatment of pathologies caused by the infection of a human or an animal by RNA type virus.

  本发明涉及由含有磷酸化化合物的转化红细胞组成的组合物，磷酸化化合物在人类或动物机体中并不自然存在，所述化合物具有以下特性： 抑制逆转录酶，以及 在红细胞中稳定。 本发明的组合物可用于治疗人或动物感染 RNA 型病毒后引起的病症。
• SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
  申请人：Janssen BioPharma, Inc.

  公开号：US20210106604A1

  公开（公告）日：2021-04-15

  Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.
• US5753221A
  申请人：——

  公开号：US5753221A

  公开（公告）日：1998-05-19
• [EN] TRANSFORMED ERYTHROCYTES, PROCESS FOR PREPARING THE SAME, AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS
  申请人：COMMUNAUTE ECONOMIQUE EUROPEENNE (CEE)

  公开号：WO1992022306A1

  公开（公告）日：1992-12-23

  (EN) The invention relates to compositions comprising transformed erythrocytes containing phosphorylated compounds, which do not naturally occur in a human or animal organism, said compounds having the properties of inhibiting the reverse transcriptase, and being stable in erythrocytes. The compositions of the invention are useful for the treatment of pathologies caused by the infection of a human or an animal by RNA type virus.(FR) L'invention se rapporte à des compositions comprenant des érythrocytes transformés contenant des composés phosphorylés qui ne se trouvent naturellement pas dans l'organisme de l'homme ou de l'animal, lesdits composés ayant les propriétés d'inhiber la transcriptase inverse, et d'être stables en érythrocytes. Les compositions de l'invention sont utilisées dans le traitement de pathologies provoquées par un virus du type à ARN ayant contaminé l'homme ou l'animal.
• [EN] 2',3'-DIDEOXYNUCLEOSIDE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVITRIDAE INFECTIONS<br/>[FR] ANALOGUES 2',3'-DIDESOXYNUCLEOSIDIQUES DESTINES AU TRAITEMENT OU A LA PREVENTION D'INFECTIONS PAR FLAVIVIRIDAE
  申请人：PHARMASSET LTD

  公开号：WO2004013298A2

  公开（公告）日：2004-02-12

  A method for the treatment or prevention of Flaviviridae infections, in particular, hepatitis C virus infection, in a host, and in particular, a human, is provided that includes administering an effective amount of a R-L- or (3-D-2',3'-dideoxynucleoside or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable diluent or excipient.